Coronavirus disease 2019 (COVID-19) is an infectious disease caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2). The most common symptoms of COVID-19 are fever, tiredness and dry cough. Apart from these common symptoms, patients have also reported other symptoms like breathlessness, diarrhea, sore throat, body pains, headache, loss of taste and smell, etc. Many of the COVID-19 positive individuals are even asymptomatic. Though most of the symptomatic patients experience mild to moderate symptoms, in some cases COVID-19 can be fatal. The group of people who are at greater risk of developing COVID-19 related health complications are older people above 60 years of age and those who have pre-existing medical issues like respiratory disorders, cardiovascular disorders, cancers, diabetes, obesity, etc.
CSIR-CCMB was the first non-ICMR lab to start COVID-19 testing in April 2020. Since then it has tested samples, trained and helped other diagnostic labs to set up their COVID-19 testing labs, and developed newer ways of COVID-19 testing.
CSIR-CCMB has studied the spread of SARS-CoV-2 in communities by studying its presence in waste water treatment plants as well as by checking for antibodies against the virus in blood of people in these communities
CSIR-CCMB is one of the ICMR-approved national biorepositories of samples from COVID-19 patients in India. We have been actively involved in isolating and culturing SARS-CoV-2 coronavirus from these samples. Using these, we have established cell-based assays to screen potential antiviral compounds, nano formulations and sterilization solutions. Based on our data, we have identified several hits […]
We have worked with Bharat Biotech through a collaborative project on vaccine development. In this project, we studied the immune response in small animals to the inactivated coronavirus. We have been working with VINS Bioproducts and University of Hyderabad to generate anti-SARS CoV-2 F(ab’)2 specific antibody fragments as a therapeutic intervention in severe COVID-19 patients. […]